Endocrine Society issues Hypertriglyceridemia Guidelines

10:02 am Health Care, Medicine
  • The Endocrine Society Guideline for the assessment of patients with hypertriglyceridemia recommends that the diagnosis be based on fasting triglyceride levels.
  • At least every 5 years, adults should be screened for hypertriglyceridemia as part of a lipid panel.
  • To facilitate assessment of cardiovascular risk, mild and moderate hypertriglyceridemia, defined as triglyceride levels of 150 to 999 mg/dL, should be diagnosed, as this condition may be a risk factor for cardiovascular disease.
  • Patients with severe and very severe hypertriglyceridemia, defined as triglyceride levels of more than 1000 mg/dL, should be considered to be at risk for pancreatitis.
  • Patients with hypertriglyceridemia should undergo evaluation for secondary causes of hyperlipidemia, such as endocrine conditions and medications, and treatment should be focused on such secondary causes.
  • Patients with primary hypertriglyceridemia should be assessed for a family history of dyslipidemia and cardiovascular disease, as well as for other cardiovascular risk factors including central obesity, hypertension, abnormalities of glucose metabolism, and liver dysfunction.
  • For patients with moderate hypertriglyceridemia, the treatment goal should be a non–high-density lipoprotein cholesterol level in agreement with NCEP-ATP guidelines.
  • For patients with mild to moderate hypertriglyceridemia, first-line therapy should be lifestyle interventions including physical activity. A combination of diet modification and pharmacotherapy may also be considered.
  • For patients with moderate to severe hypertriglyceridemia, treatment with fibrates, niacin, and/or omega-3 fatty acids alone or in combination with statins should be considered.
  • A fibrate should be used as a first-line agent in patients with severe or very severe hypertriglyceridemia, in addition to reduction of dietary fat and simple carbohydrate intake.
  • Statins should not be used as monotherapy for severe or very severe hypertriglyceridemia, but they may be useful for the treatment of moderate hypertriglyceridemia when indicated to modify cardiovascular risk.

Comments are closed.